Higher initial dose of Lu-177-PSMA-617 for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial is testing if a higher first dose of Lu-177-PSMA-617, a targeted radiation therapy, can improve outcomes for men with metastatic castration-resistant prostate cancer that shows up on a PSMA PET scan. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have metastatic castration-resistant prostate cancer that is confirmed by a PSMA PET scan (where the cancer shows up brighter than the liver).
- You must have recovered from side effects of prior treatments to at most a mild level (grade 2 or less).
- You must be 18 years or older.
- You must be active and able to care for yourself (ECOG performance status 0 or 1).
- You must have adequate blood counts (ANC ≥ 1500, platelets ≥ 150,000, hemoglobin ≥ 10.0) and kidney function (eGFR ≥ 60).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
This trial tests if a second round of a targeted radiation therapy (177Lu-PSMA-617) can help men whose prostate cancer has returned after a successful first treatment. It is for men whose cancer has stopped responding to hormone therapy and chemotherapy, and whose PSA levels have risen again after a prior good response to this drug.
This study tests a combination of focused radiation (SBRT) and a targeted radioactive drug (Lutetium PSMA) for men with prostate cancer that has spread to nearby lymph nodes or has high-risk features but has not yet reached distant organs. The goal is to see if this approach is safe and effective.
This trial tests a flexible dosing schedule of a targeted radiation drug (Lu-PSMA) for men with metastatic prostate cancer that has stopped responding to hormone therapy and chemotherapy. It aims to see if adjusting the treatment schedule can improve outcomes while reducing side effects.
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
Hear when a new Metastatic Castration-Resistant Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.